181 related articles for article (PubMed ID: 11729364)
1. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Voss R
J Thromb Thrombolysis; 2001 Oct; 12(2):129-39. PubMed ID: 11729364
[TBL] [Abstract][Full Text] [Related]
2. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
Harder S; Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Glusa E; Mascelli MA; Marciniak SJ; Just A; Lösche W; Breddin HK
Thromb Res; 2001 Apr; 102(1):39-48. PubMed ID: 11323013
[TBL] [Abstract][Full Text] [Related]
3. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition.
Osende JI; Fuster V; Lev EI; Shimbo D; Rauch U; Marmur JD; Richard M; Varon D; Badimon JJ
Circulation; 2001 Mar; 103(11):1488-91. PubMed ID: 11257073
[TBL] [Abstract][Full Text] [Related]
4. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
Smith JW; Steinhubl SR; Lincoff AM; Coleman JC; Lee TT; Hillman RS; Coller BS
Circulation; 1999 Feb; 99(5):620-5. PubMed ID: 9950658
[TBL] [Abstract][Full Text] [Related]
5. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.
White MM; Krishnan R; Kueter TJ; Jacoski MV; Jennings LK
J Thromb Thrombolysis; 2004 Dec; 18(3):163-9. PubMed ID: 15815877
[TBL] [Abstract][Full Text] [Related]
6. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
7. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
Bertram U; Moser M; Peter K; Kuecherer HF; Bekeredjian R; Straub A; Nordt TK; Bode C; Ruef J
J Thromb Thrombolysis; 2002 Dec; 14(3):197-203. PubMed ID: 12913399
[TBL] [Abstract][Full Text] [Related]
8. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
10. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
Simon DI; Liu CB; Ganz P; Kirshenbaum JM; Piana RN; Rogers C; Selwyn AP; Popma JJ
Catheter Cardiovasc Interv; 2001 Apr; 52(4):425-32. PubMed ID: 11285593
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
Neumann FJ; Hochholzer W; Pogatsa-Murray G; Schömig A; Gawaz M
J Am Coll Cardiol; 2001 Apr; 37(5):1323-8. PubMed ID: 11300442
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
Storey RF; Wilcox RG; Heptinstall S
Circulation; 1998 Oct; 98(16):1616-21. PubMed ID: 9778326
[TBL] [Abstract][Full Text] [Related]
14. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
15. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
[TBL] [Abstract][Full Text] [Related]
16. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
17. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
Speich HE; Earhart AD; Hill SN; Cholera S; Kueter TJ; Smith JN; White MM; Jennings LK
J Thromb Haemost; 2009 Jun; 7(6):983-91. PubMed ID: 19548907
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
Kereiakes DJ; Mueller M; Howard W; Lacock P; Anderson LC; Broderick TM; Roth EM; Whang DD; Abbottsmith CW
J Thromb Thrombolysis; 1999 Jun; 7(3):265-76. PubMed ID: 10375388
[TBL] [Abstract][Full Text] [Related]
19. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
Wheeler GL; Braden GA; Steinhubl SR; Kereiakes DJ; Kottke-Marchant K; Michelson AD; Furman MI; Mueller MN; Moliterno DJ; Sane DC
Am Heart J; 2002 Apr; 143(4):602-11. PubMed ID: 11923796
[TBL] [Abstract][Full Text] [Related]
20. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
Storey RF; May JA; Wilcox RG; Heptinstall S
Thromb Haemost; 1999 Oct; 82(4):1307-11. PubMed ID: 10544919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
